ESC: Otamixaban Fails in ACS (CME/CE)

AMSTERDAM (MedPage Today) -- The novel drug otamixaban failed to make a difference in preventing ischemic events among patients with non-ST-segment elevation myocardial infarction when compared with heparin and eptifibatide (Integrilin), a study found.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news